Premium
Peroxiredoxin‐I is an autoimmunogenic tumor antigen in non‐small cell lung cancer
Author(s) -
Chang Jong Wook,
Lee Seung Hee,
Jeong Ju Yeon,
Chae Ho Zoon,
Kim Young Chul,
Park Zee-Yong,
Yoo Yung Joon
Publication year - 2005
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2005.04.028
Subject(s) - autoantibody , lung cancer , antigen , peroxiredoxin , antibody , cancer research , immune system , immunology , cancer , blot , serology , medicine , biology , pathology , gene , peroxidase , biochemistry , enzyme
In eukaryotic cells, peroxiredoxins are both antioxidants and regulators of H 2 O 2 ‐mediated signaling. We previously found that peroxiredoxin‐I (Prx‐I) was overexpressed in non‐small cell lung cancer (NSCLC) tissue. Since overexpressed protein can induce a humoral immune response, we examined whether serum from NSCLC patients exhibited immunoreactivity against Prx‐I using Western blotting. We found that 25 (47%) of 53 NSCLC patients tested had autoantibodies against Prx‐I in their sera, whereas such activity was detected in 4 (8%) sera from 50 healthy subjects. Prx‐I itself was detected in the sera from 18 (34%) of 53 NSCLC patients but in only 1 (2%) serum from 50 controls. Moreover, 17% of NSCLC sera were positive to both Prx‐I antibody and antigen but none in control sera. The data indicate both Prx‐I autoantibody and circulating antigen are potential biomarkers for use in serological diagnosis of NSCLC. Interestingly enough, we found that Prx‐I was secreted by lung adenocarcinoma cells (A549) but not by non‐cancer lung cells (BEAS 2B) or breast cancer cells (MCF7). This cell culture study suggests the possibility of Prx‐I secretion from NSCLC tumor tissues.